PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC
Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.
PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC
một ngày trước